SSA
SONN

Schonfeld Strategic Advisors’s Sonnet BioTherapeutics SONN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio SONN Stock Details SONN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5
Closed -$31K – 1856
2020
Q3 		$31K Buy
+5
New +$36K ﹤0.01% 1313

Other funds holding SONN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MSFS
Main Street Financial Solutions Newtown, Pennsylvania $1.34B AUM 19.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Schonfeld Strategic Advisors's SONN Position: Q4 2020 in Review

Schonfeld Strategic Advisors sold out of Sonnet BioTherapeutics (SONN) in Q4 2020, closing a stake of 5 shares — an estimated $31K sold.

Schonfeld Strategic Advisors first reported a position in SONN in Q3 2020 and held it in 1 quarter. The position peaked at $31K in Q3 2020. 8 funds tracked by Wall St. Rank hold SONN as of Q4 2020.

  • Schonfeld Strategic Advisors reported no remaining Sonnet BioTherapeutics position as of Q4 2020 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 5 Sonnet BioTherapeutics shares in Q4 2020, an estimated $31K.
  • Schonfeld Strategic Advisors first reported a position in Sonnet BioTherapeutics in Q3 2020 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Sonnet BioTherapeutics position peaked at $31K in Q3 2020.
  • 8 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2020.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.